JMJakub Marek

Jakub Marek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jakub Marek has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantitative brain volumetry in neurological disorders: from disease mechanisms to software solutions

    by Jakub Marek, Dominika Bachurska, Tomasz Wolak, Agata Borowiec, Michał Sajdek, Edyta Maj

    Quantitative magnetic resonance imaging (MRI) volumetry has become a pivotal component in modern neurology, bridging the gap between detailed neuroimaging and clinical decision-making. By employing advanced imaging techniques like 3D T1-weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) sequences, MRI volu­metry enables clinicians to objectively quantify brain volume changes associated with neurological conditions such as Alzheimer’s disease, multiple sclerosis, epilepsy, and myotonic dystrophy. Automated segmentation tools, including FreeSurfer, NeuroQuant, volBrain, and AccuBrain, facilitate precise and reproducible analysis of structural brain changes, contributing significantly to early diagnosis, patient monitoring, and therapeutic planning. In Alzheimer’s disease, volumetric MRI enables the detection of early hippocampal and temporal lobe atrophy, providing a crucial biomarker for diagnosis and monitoring disease progression. Similarly, in multiple sclerosis, volumetric analyses quantify grey and white matter degeneration, reflecting motor and cognitive impairment severity. Moreover, quantitative MRI techniques precisely delineate structural abnormalities like hippocampal sclerosis and focal cortical dysplasia in epilepsy, crucial for accurate surgical intervention. Ongoing advances in artificial intelligence and machine learning are set to further enhance these volumetric approaches, addressing current limitations such as inter-observer variability and expanding their clinical applicability. This review outlines the existing landscape and future trajectory of quantitative MRI volumetry, underscoring its expanding role in clinical neurology and personalised medicine.


  • Open Access

    The Treatment of Depression in Patients with Heart Failure

    by Dominika Bachurska, Jakub Marek, Oliwia Grygorczuk, Zuzanna Czach

    This narrative review critically examines the utilization of Selective Serotonin Reuptake Inhibitors (SSRIs) in managing coexisting depression and heart failure (HF), integrating findings from various studies, clinical trials, and observational data. SSRIs, pivotal in treating mood and anxiety disorders by elevating synaptic serotonin levels, have been observed to potentially impact cardiovascular health. Specifically, SSRIs like sertraline show promise in enhancing endothelial function and exerting anti-inflammatory effects, which are beneficial in conditions like HF with preserved ejection fraction (HFpEF). Furthermore, SSRIs demonstrate favorable outcomes in reducing platelet aggregation and modulating the renin-angiotensin-aldosterone system (RAAS), suggesting a multifaceted role in HF management. However, their safety profile, particularly concerning bleeding risks, QTc prolongation, and drug interactions, necessitates careful consideration. Despite theoretical and molecular evidence supporting SSRIs' beneficial effects in HF, clinical data remain inconclusive, highlighting the need for further research. This review aims to provide a comprehensive understanding of SSRIs' effectiveness, safety, and potential benefits in treating depression and HF, offering insights for evidence-based decision-making and future research directions.